Globus Medical, Inc. (GMED) Up 5.5% — Is This a Buying Opportunity?
Key Points
Globus Medical, Inc. (GMED) extended its recent upswing with a strong session, closing at $95.54 on the NYSE, up 5.52% from the prior close of $90.54 and gaining $5.00 on the day. The advance pushed shares to a fresh 52-week high, edging past the previous peak of $94.93 set on Jan. 30, 2025. That breakout above prior resistance underscores bullish activity, as the stock continues to gain ground in an already positive trend. The move keeps the price firmly in the upper end of its annual range, highlighting strong performance relative to its own recent history.
Trading activity was robust, with volume of 2,478,821 shares easily topping the 90-day average of 1,589,385. This elevated turnover suggests the latest price surge came with strong participation, reinforcing the sense of momentum rather than a thinly traded spike. Within the broader health care space, GMED’s sharp single-session gain stands out against more measured moves typically seen in larger peers such as Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), UnitedHealth Group (UNH), and Merck (MRK). In that context, Globus Medical appears to be gaining ground at a faster clip, with price action that has recently been more aggressive than many of its sector counterparts. Overall, the combination of a new 52-week high, a 5.52% daily jump, and above-average volume paints a distinctly bullish near-term picture for the stock’s trading behavior.
Why Globus Medical, Inc. Price is Moving Higher
Globus Medical’s latest surge is being driven squarely by fundamental catalysts and increasingly bullish sentiment. The stock broke out to a new 12‑month high after the company released preliminary Q4 and full‑year 2025 results showing powerful top-line momentum: Q4 sales are expected to come in around $823.2 million, up 25.2% year over year, with full‑year 2025 revenue of roughly $2.936 billion, a 16.5% increase. Management paired those figures with initial 2026 revenue guidance of $3.18 billion–$3.22 billion, comfortably ahead of prior consensus, and highlighted strong U.S. spine growth, record Enabling Technologies sales, and steady progress integrating the NuVasive and Nevro acquisitions. That blend of double‑digit growth, healthy 15.29% profit margins, and a clear growth roadmap has energized investors and helped push the shares higher.
Wall Street’s reaction has added fuel to the move. The stock jumped more than 8% in overnight and next‑day trading following the update, as several analysts raised their price targets and reiterated positive ratings. Jefferies notably lifted its target from $105 to $115, citing better‑than‑expected preliminary Q4 revenue versus consensus and 2026 EPS guidance of $4.30–$4.40 that tops prior expectations. Barclays, Truist and Canaccord also boosted targets, and MarketBeat now highlights an average target near $97 with a “Moderate Buy” consensus. Against a backdrop of solid demand for musculoskeletal and spine procedures and growing adoption of robotics and navigation technologies, investors see Globus as gaining share and executing on a robust product pipeline, helping sustain the current upside momentum.
What is the Globus Medical, Inc. Rating - Should I Buy?
Weiss Ratings assigns GMED a C rating. Current recommendation is Hold. For investors, that places Globus Medical, Inc. in the middle of the pack on a risk-adjusted basis, but with several notable strengths that may appeal to those looking for long-term exposure to the Health Care space.
The standout positives come from the Excellent Growth Index and Excellent Solvency Index. GMED is expanding at a healthy pace, with revenue growth of 22.91%, supported by a solid profit margin of 15.29%. That growth is being pursued from a position of financial strength, giving the company flexibility to invest, navigate industry cycles and potentially capitalize on new opportunities. The Good Efficiency Index, including a 10.01% return on equity, signals that management is generating reasonable returns on the capital it deploys.
Balancing these strengths, the Total Return Index is Fair and the Volatility Index is Weak, indicating that shareholders have not yet been fully rewarded for the company’s operational momentum and may experience choppier price swings than more established blue chips. A forward P/E of 29.21 prices in continued growth, which can add pressure if expectations are not met. In the Health Care sector, Globus Medical’s C (Hold) rating is broadly in line with peers such as AbbVie Inc. (ABBV, C), UnitedHealth Group Incorporated (UNH, C), and Merck & Co., Inc. (MRK, C), while trailing higher-rated names like Eli Lilly and Company (LLY, B) and Johnson & Johnson (JNJ, B).
Overall, the C (Hold) rating indicates a stock with meaningful growth and balance sheet advantages, but with a risk/return profile that, at this stage, remains average relative to alternatives.
About Globus Medical, Inc.
Globus Medical, Inc. is a health care equipment company focused on advancing musculoskeletal care through innovative medical device technologies. The company develops, manufactures and markets a broad portfolio of products used primarily in spine surgery, orthopedics and related specialties. Its offerings span spinal fixation systems, interbody devices, motion preservation technologies, and enabling technologies that support planning and execution in the operating room. Globus serves hospitals, ambulatory surgery centers and specialized surgical practices worldwide, working closely with spine surgeons and orthopedic specialists to address complex degenerative, deformity, trauma and tumor indications.
A key point of differentiation for Globus Medical is its emphasis on product innovation and technology integration across the continuum of care. The company has been a leader in the adoption of minimally invasive techniques and enabling technologies, including advanced imaging, navigation and robotic-assisted systems designed to improve surgical precision and workflow efficiency. In addition to core spine implants and instrumentation, Globus has expanded into trauma, joint reconstruction and biologics solutions, building a comprehensive musculoskeletal platform. Its specialized distribution network, surgeon education programs and focus on clinical collaboration help reinforce its position in the competitive health care equipment and services industry, particularly in the global spine and orthopedic device markets.
Investor Outlook
With Globus Medical, Inc. (GMED) carrying a C (Hold) Weiss Rating, the stock appears positioned for potential continued gains if it can build on recent operational and share-price momentum. Investors may want to watch how Health Care sector sentiment, innovation in medical technologies, and any shifts in risk or return metrics influence whether this Hold profile improves over time. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--